Liqui-Patch: Sanity Group and epinamics launch strategic partnership for transdermal cannabinoid applications

Berlin, September 22, 2021 – Berlin-based health and life science company Sanity Group and Berlin-based tech company epinamics are launching a strategic innovation partnership: Sanity Group will receive exclusive usage and marketing rights for epinamics’ patented Liqui-Patch® technology for all cannabinoid market segments and markets in the EU, UK and Switzerland.

Liqui-Patch® is an innovative, film-forming spray solution for the transdermal application of active ingredients. A team of researchers around epinamics founder Prof. Dr. Wolfgang Kehr developed the technology over several years and spun it off as a management spin-off from Bayer-Schering. Based on the Liqui-Patch® technology, the Sanity Group will break new ground in the transdermal delivery of cannabinoids. Products are planned in the medical field as well as in the wellbeing and sports sector.

“With Liqui-Patch® transdermal technology, we are pushing open the door to the cannabis market of the future: smart, innovative products with high therapeutic benefits make medical cannabis a strong option for entirely new patient groups,” says Thimo V. Schmitt-Lord, Director Market Development & Sector Innovation at Vayamed, the pharmaceutical subsidiary of Sanity Group. “Liqui-Patch® also represents Vayamed’s brand vision in a special way: medicine from nature, tailored for patient well-being.”

Active ingredient patch for spraying

Compared to conventional dermal or transdermal applications, Liqui-Patch®, which is sprayed onto the skin as a transparent film with a pump spray, offers far-reaching advantages: The spray is transparent, dries quickly on the skin and does not smear; skin irritation, such as that caused by the adhesive strips of conventional solid patches, can be avoided by the technology. In addition to high bioavailability, it also provides a constant release of active ingredients over many hours. Furthermore, it offers a safe alternative to the use of gels containing active ingredients, where there is always a risk of active ingredient transfer. Last but not least, the Liqui-Patch® enables more efficient use of active ingredients for almost all disease areas compared to conventional methods.

“Anyone who has ever worn an active ingredient patch for several days knows the problem: the skin is irritated and painful. Active ingredient patches, which transport drugs through the skin into the bloodstream, have become established. However, they have some disadvantages, often leading to restricted freedom of movement and painful skin reactions. We were looking for an alternative to this and were able to develop it in the form of the Liqui-Patch®,” says epinamics Managing Director Prof. Dr. Kehr.

For more information on the Liqui-Patch, visit


About the Sanity Group

The Sanity Group has set itself the goal of improving people’s quality of life through the sensible use of cannabis in Europe. In addition to pharmaceuticals, the focus is also on consumer health products based on cannabinoids. In parallel, Sanity Group is also working and researching new medical products, innovative dosage forms, and technological products and services to further develop the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 100 people at its headquarters in Berlin-Mitte and its research site near Frankfurt am Main. Sanity Group brands include Vayamed (pharmaceuticals), VAAY (CBD products) and This Place (functional cosmetics). The company is supported strategically and financially by Redalpine, HV Capital, Calyx, Navy Capital, Bitburger Ventures, SevenVentures and various business angels such as Casa Verde founder Karan Wadhera, music producer, TV presenter Klaas Heufer-Umlauf, professional soccer player Mario Götze and model Stefanie Giesinger. More information at

About epinamics

Berlin-based epinamics GmbH is a specialised and globally oriented development company in the field of advanced drug delivery. The owner-managed company focuses on the Liqui-Patch®, a patent-protected platform technology for dermal and transdermal delivery of active ingredients. The Liqui-Patch® can be conveniently and safely applied to the skin and forms an invisible film within 90 seconds from which the respective active ingredient is released. The procedure replaces the currently prevailing patch technology (i.e. plastic stick-on patches), as it is lighter, gentler on the skin and completely inconspicuous to apply.